Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Research & Development (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Research & Development for 6 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 31.73% to $20.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $114.2 million, a 6.33% increase, with the full-year FY2025 number at $114.2 million, up 6.33% from a year prior.
  • Research & Development was $20.0 million for Q4 2025 at TScan Therapeutics, down from $31.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $32.6 million in Q2 2025 to a low of $7.3 million in Q1 2021.
  • A 5-year average of $20.7 million and a median of $21.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 144.38% in 2021, then crashed 31.73% in 2025.
  • TScan Therapeutics' Research & Development stood at $12.6 million in 2021, then increased by 23.76% to $15.6 million in 2022, then skyrocketed by 43.59% to $22.4 million in 2023, then surged by 31.01% to $29.4 million in 2024, then plummeted by 31.73% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Research & Development are $20.0 million (Q4 2025), $31.7 million (Q3 2025), and $32.6 million (Q2 2025).